2018 News Releases

News Releases | Events
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International ConferenceJuly 17, 2018NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 at the 2018 Alzheimer’s Association International Conference (AAIC) on July 23, 2018 in Chicago, IL. AXS-05 is a novel, oral, investigational medicine consisting of dextromethorphan and bupropion, in late-stage development for the tr... Read MoreAxsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive DisorderJune 5, 2018First patient enrolled in the ASCEND study Trials in two mood disorders now underway with AXS-05 NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in the ASCEND (Assessing Clinical Episodes in Depression) study, a Phase 2 randomized, controlled trial of AXS-05 in major depressive disorder (MDD). AXS-0... Read MoreAxsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual MeetingMay 29, 2018NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Phase 1 pharmacokinetic and mechanism of action data and analyses for AXS-05, its novel glutamatergic and monoaminergic product candidate, will be presented at the 2018 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) on May 31, 2018... Read MoreAxsome Therapeutics to Present at the 2018 BIO International ConventionMay 22, 2018NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate overview at the 2018 Biotechnology Innovation Organization (BIO) International Convention on June 5, 2018 at 1:45 PM Eastern Time. The convention will be held at the Boston Convent... Read MoreAxsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 8, 2018Company to host conference call today at 8:00 AM Eastern NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2018. “We have achieved several key clinical milestones in the first five months of 2018 and are on track to announce results from two late-stage clin... Read MoreAxsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric AssociationMay 3, 2018NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 (bupropion and dextromethorphan), its novel glutamatergic and monoaminergic product candidate, at the 2018 Annual Meeting of the American Psychiatric Association on May 8, 2018 in New York, NY. The poster will highlight the anti-in... Read MoreAxsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018May 1, 2018Axsome to host conference call and webcast on Tuesday, May 8, 2018 at 8:00 AM Eastern Time NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2018 on Tuesday, May 8, 2018 before the opening of the U.S. financial markets. Axsome’s management team wil... Read MoreAxsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant DepressionApril 26, 2018Independent Data Monitoring Committee recommends trial continuation Second interim analysis anticipated second half of 2018 for efficacy NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a positive outcome of the interim futility analysis for the STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depress... Read MoreAxsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceApril 24, 2018NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a research and development (R&D) day in New York City today with key opinion leaders (KOLs), to highlight the company’s CNS product candidate AXS-05 (bupropion and dextromethorphan) and unmet needs in depression, agitation associated with Alzheimer’s disease, and n... Read MoreAxsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking CessationApril 23, 2018Trial being conducted in collaboration with Duke University NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the enrollment of the first patient into a Phase 2 trial of AXS-05 for smoking cessation treatment. The trial is being conducted under a research collaboration between Duke University and Axsome Therapeu... Read MoreAxsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial OfficerApril 19, 2018NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Nick Pizzie, CPA, MBA, as Chief Financial Officer (CFO), effective May 16, 2018. “Nick’s diverse financial experience and expertise make him a strong addition to the Axsome team,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. ... Read MoreAxsome Therapeutics to Participate in the Leerink Partners’ 2018 CNS DayApril 11, 2018NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, and Cedric O’Gorman, M.D., Axsome’s Senior Vice President of Clinical Development and Medical Affairs, will participate in the Leerink Partners’ CNS Day on April 18, 2018 at 8:40 AM Eastern Time, in Ne... Read MoreAxsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceMarch 27, 2018NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a research and development (R&D) day with key opinion leaders (KOLs), highlighting the company’s CNS product candidate AXS-05, and unmet needs in depression, agitation associated with Alzheimer’s disease, and nicotine dependence, on Tuesday, ... Read MoreAxsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences ConferenceMarch 26, 2018NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference on April 10, 2018 at 1:45 PM Central European Time. The conference will be held at Le Meridien Beach Plaz... Read MoreAxsome Therapeutics to Present at 17th Annual Needham Healthcare ConferenceMarch 19, 2018NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 17th Annual Needham Healthcare Conference on March 28, 2018 at 10:00 AM Eastern Time. The conference will be held at The Westin New York Grand Central Hotel in ... Read MoreAxsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental NeurotherapeuticsMarch 12, 2018NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on AXS-05, its novel glutamatergic and monoaminergic product candidate, at the 20th annual meeting of the American Society for Experimental Neurotherapeutics (ASENT), held in Rockville, MD, March 7-10, 2018. Axsome delivered three presentations, t... Read MoreAxsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateMarch 7, 2018Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2017. “In 2017 we significantly expanded our pipeline ... Read MoreAxsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018February 28, 2018Axsome to host conference call and webcast on Wednesday, March 7, 2018 at 8:00 AM Eastern Time NEW YORK, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for fiscal year 2017 on Wednesday, March 7th, 2018 before the opening of the U.S. financial markets. Axsome’s management team w... Read MoreAxsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and DextromethorphanFebruary 26, 2018Chirally pure and stable single enantiomers of bupropion achieved AXS-09 consists of esbupropion and dextromethorphan for CNS disorders Esbupropion is the chirally pure S-enantiomer of bupropion AXS-09 results in substantial increases in dextromethorphan plasma levels (p<0.0001) NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disor... Read MoreAxsome Therapeutics to Present at 2018 BIO CEO & Investor ConferenceFebruary 5, 2018NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 2018 BIO CEO & Investor Conference on February 12th, 2018 at 10:00 AM Eastern Time. The conference will be held at the New York Marriott Marquis in New York, NY.... Read MoreAxsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 TrialJanuary 9, 2018COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone resorption confirms potent pharmacologic activity Company to host conference call today at 8:00 AM Eastern NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central n... Read More
Print PageE-mail PageRSS FeedsE-mail AlertsFinancial Tear Sheet